Browsing by Yonsei Author : Heo, Seong Gu

eperson profile image
Name :
Heo, Seong Gu [허성구]
Department :
College of Medicine (의과대학) - BioMedical Science Institute (의생명과학부)

Keyword Cloud

Researcher Network

Showing results 1 to 12 of 12

This table browses all dspace content
Issue DateTitleJournal Title
2024Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH TrialJOURNAL OF CLINICAL ONCOLOGY
2023Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCClinical Cancer Research
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapyTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityFrontiers in Oncology
2022SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsClinical & Translational Immunology
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical modelsTherapeutic Advances in Medical Oncology
2021A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinomaCancer Medicine
2021Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung AdenocarcinomaClinical Cancer Research
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEuropean Journal of Cancer
2021The Liability Threshold Model for Predicting the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Multi-Cohort Study of Korean AdultsMETABOLITES
2020Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLCCANCER DISCOVERY
2020Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer CLINICAL CANCER RESEARCH
1

Browse

Links